According to MarketsandMarkets™, the Cardiac Marker Testing Market is projected to grow from approximately USD 5.54 billion in 2026 to USD 9.06 billion by 2031, registering a CAGR of 10.3% during the forecast period.
The comprehensive market study includes 457 market data tables and 55 figures across 372 pages, providing detailed insights, competitive analysis, market trends, growth opportunities, and an in-depth table of contents for the “Cardiac Marker Testing Market – Global Forecast to 2031.”
Cardiac Marker Testing Market Size and Forecast
- Market Size Data Available: 2025–2031
- 2026 Market Size: USD 5.54 billion
- 2031 Projected Market Size: USD 9.06 billion
- CAGR (2026–2031): 10.3%
Key Cardiac Marker Testing Market Trends and Insights
The global cardiac marker testing industry is witnessing significant technological and clinical developments. The reagents & kits segment is expected to record the highest growth rate of approximately 11%. Troponin I & T dominated the market with a 40.3% share in 2025, reflecting their critical role in diagnosing myocardial injury and acute cardiac conditions.
Laboratory-based tests accounted for the largest market share of 74.7% in 2025, supported by established diagnostic infrastructure and high testing volumes. Meanwhile, multiplex assays are projected to grow at the highest CAGR of 11.6%, driven by increasing demand for simultaneous biomarker detection and comprehensive cardiac risk assessment.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64885447
Growing Demand for Rapid Cardiac Diagnostics Drives Market Expansion
The increasing adoption of point-of-care testing solutions and the rising demand for rapid diagnostic results in emergency and critical care environments are major factors accelerating the cardiac marker testing market.
The growing global geriatric population and the increasing prevalence of lifestyle-related conditions, including obesity and diabetes, are contributing to a higher burden of cardiovascular diseases. As a result, healthcare providers are increasingly focusing on early diagnosis, rapid clinical decision-making, and effective cardiac risk assessment.
The shift toward decentralized healthcare systems is further creating opportunities for portable and point-of-care cardiac testing solutions. In addition, increasing research and development activities focused on multiplex biomarker testing technologies are expected to support continued market expansion.
Technological Advancements Transform Cardiac Marker Testing
Technological innovation continues to reshape the cardiac marker testing landscape. The development of high-sensitivity cardiac biomarker assays, increased adoption of laboratory automation, and integration of digital health and data management platforms are improving diagnostic efficiency and clinical decision-making.
Advanced immunoassay technologies, multiplex testing platforms, and highly specific biomarker assays are enabling earlier and more accurate detection of cardiac conditions. These innovations allow diagnostic laboratories and healthcare providers to implement more reliable, efficient, and scalable testing workflows.
Furthermore, modern cardiac marker testing solutions are increasingly being validated across diverse patient populations, helping clinicians assess complex clinical conditions and improve patient management strategies.
Reagents & Kits Segment Holds a Major Market Share
Based on product, the cardiac marker testing market is segmented into reagents & kits and instruments. The reagents & kits segment accounted for the larger market share in 2026.
Growth in this segment is primarily driven by the increasing incidence of cardiovascular diseases, growing demand for advanced diagnostic solutions, and the need for rapid and accurate cardiac test results.
The recurring use of reagents and testing kits across diagnostic laboratories and healthcare facilities also supports sustained demand. At the same time, the expansion of diagnostic laboratory infrastructure and continued improvements in automated testing systems are contributing to the adoption of advanced cardiac marker testing instruments.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=64885447
Point-of-Care Testing Segment to Register the Highest Growth
Based on end user, the cardiac marker testing market includes diagnostic laboratories, academic institutes, and point-of-care testing facilities.
The point-of-care testing segment is projected to register the highest growth rate during the forecast period. This expansion is primarily attributed to the increasing need for rapid test results in emergency departments, intensive care units, and critical care environments.
The rising prevalence of cardiovascular diseases and the growing importance of immediate clinical decision-making are encouraging healthcare providers to adopt point-of-care cardiac marker testing solutions.
Additionally, the increasing emphasis on decentralized patient care and improved patient outcomes through early diagnosis is expected to accelerate the adoption of rapid cardiac biomarker testing technologies.
North America Leads the Global Cardiac Marker Testing Market
The global cardiac marker testing market is analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest market share in 2025 and continued to dominate the cardiac marker testing market in 2026. The region’s leadership is supported by its advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and significant volume of diagnostic testing procedures.
The strong presence of sophisticated diagnostic laboratories and hospitals also contributes to market growth. Additionally, stringent regulatory requirements related to diagnostic accuracy, testing quality, and early disease detection are driving the adoption of advanced cardiac marker testing technologies across the region.
Inquire Before Buying:
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=64885447
Top Companies in the Cardiac Marker Testing Market
The cardiac marker testing market features several leading global diagnostics and life sciences companies. Key market players include:
- Siemens Healthineers (Germany)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Danaher Corporation (US)
- Abbott Laboratories (US)
- Thermo Fisher Scientific Inc. (US)
- BD (US)
- Bio-Rad Laboratories, Inc. (US)
- Revvity, Inc. (US)
- DiaSorin S.p.A. (Italy)
- Quidel Corporation (US)
These companies are focusing on product innovation, high-sensitivity cardiac assays, automated diagnostic platforms, point-of-care testing technologies, and strategic partnerships to strengthen their positions in the global cardiac marker testing market.
Future Outlook of the Cardiac Marker Testing Market
The cardiac marker testing market is positioned for strong growth as healthcare systems increasingly prioritize early cardiovascular disease detection, rapid diagnostics, and decentralized testing.
The growing adoption of high-sensitivity biomarker assays, multiplex testing technologies, laboratory automation, and point-of-care diagnostic solutions is expected to transform cardiac disease diagnosis and patient management.
With the market projected to reach USD 9.06 billion by 2031 at a CAGR of 10.3%, cardiac marker testing is expected to remain an important area of innovation and investment within the global diagnostics industry.
